New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity

AstraZenecaIn a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity following significant revision of its approach and adoption of a '5R framework' - right target, right patient, right tissue, right safety, right commercial potential.

The publication explains how adoption of the research unit's 5R framework has guided successful, efficient drug discovery and development whilst financial investment in R&D has remained unchanged. It shows that the research unit’s success rate in discovering new compounds, which then progress through the pipeline to completion of Phase III clinical trials, has increased from 4% in the period 2005-2010 to 19% in the period 2012-2016 based on the 5R framework.

The improvement positions R&D productivity above the pharmaceutical industry average of 6% for small molecules in the 2013-2015 timeframe(2). The transformation accompanied a strategic re-focusing on three main therapy areas: Oncology, Cardiovascular & Metabolic Diseases and Respiratory.

Mene Pangalos, Executive Vice President, IMED Biotech Unit and Business Development, said: "In a high-risk industry facing a well-documented decline in productivity2, I am proud to see the impact of our 5R strategy on our R&D success. There is still room for improvement, but we expect the focus on scientific rigour to further enhance our capability for translating science into innovative medicines for patients."

The IMED Biotech Unit’s 5R framework focuses on quality rather than quantity at all stages of drug discovery and development. Hence, the number of projects in discovery has decreased while their likelihood of success has increased. Other key factors include investment in state-of-the-art technologies, such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and next-generation sequencing, to produce better quality drug candidates for development, as well as a change in culture to focus on the science rather than the commercial opportunity.

Components of the increased R&D productivity include:

  • Early identification of patients most likely to benefit from treatment led to 62% of projects progressing to the next phase of development compared with 46% without prospective patient selection. Today, >90% of projects in the IMED Biotech Unit pipeline have a patient selection approach.
  • Progression to Phase III trials maintained at 2010 levels despite 50% lower number of candidate drugs in development.
  • Greater than four-fold reduction in preclinical project safety due to adoption of best practice predictive and translational science.
  • 70% of projects where proof-of-mechanism (POM) was demonstrated were associated with increased clinical success compared with 26% where POM was not demonstrated. In the 2005-2010 pipeline cohort fewer than 5 projects demonstrated POM compared with 29 in the 2012-2016 cohort. POM is a demonstration that a new compound reaches its target organ(s), interacts with its molecular target, and affects the biology of the target cells as intended.

The increased R&D productivity is mirrored by a substantial rise in the number of peer-reviewed research publications published by the IMED Biotech Unit’s scientists, especially in high-impact journals.

About IMED Biotech Unit

IMED Biotech Unit is one of two global research and early development arms of AstraZeneca, focusing on advancing small molecules, oligonucleotides and other emerging technologies and drug discovery platforms. The Biotech Unit conducts innovative discovery research and early-stage development from initial target selection to Phase II trial completion.

The second global research and early development arm is MedImmune which is responsible for global biologics R&D, including immunotherapies.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

1. Morgan P, Brown DG, Lennard S, Anderton M, Barett JC, Eriksson U, Fidock M, Hamren B, Johnson A, March RE, Matcham J, Mettetal J, Nichols DJ, Platz S, Rees S, Snowden MA, Pangalos MN. (2011) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery (In Press).
2. Data sourced from CMR International’s 2016 Global R&D Performance Metrics Programme)

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...